Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (June 2023)
37 slides from Maat Pharma's investor presentation, June 2023
Slide 1: MaaT Pharma: Microbiota as a Therapy
MaaT Pharma Microbiota as a Therapy June 2023
Slide 2: Disclaimer
Disclaimer This document has been prepared by MaaT Pharma (the "Company") and is for information and No representation, warranty or undertaking, express or implied, is made as to the accuracy, background purposes only. completeness or appropriateness of the information and opinions contained in this
Slide 3: A Uniquely-Positioned Microbiome Company
A Uniquely-Positioned Microbiome Company Listed on Euronext (MAAT) pioneering development of Microbiome Ecosystem Therapies to address hematological malignancies and oncology Differentiated approach, lead asset in Phase III in aGvHD Multi-asset clinical and preclinical pipeline with near-term, value
Slide 4: Host–Microbiota Interactions are Critical for a Functional Immune System
Host – Microbiota Interactions are Critical for a Functional Immune System A rich and diversified gut ecosystem actively modulates the immune system functionality • A diversified microbiome contributes to the education and modulation of our immune system throughout life • Bacterial richness and mucu
Slide 5: Diversity matters! Higher gut microbiome diversity is associated with…
Diversity matters! Higher gut microbiome diversity is associated with … Liquid Tumors Solid Tumors Higher survival rate in patients Lower incidence and lower Higher response rate to ICI* in patients receiving allo-HSCT *,1 mortality from aGvHD*,2 with metastatic melanoma3 -30% mortality aGvHD 1 MaaT
Slide 6: MaaT Pharma's MET platform has generated a diverse line of product candidates
MaaT Pharma’s Microbiome Ecosystem Therapy (MET) platform has generated a diverse line of product candidates Microbiome Ecosystem cGMP Platform Therapies (MET) Native Co-cultured MaaT013 MaaT033 MaaT03X ✓ Indication-specific designed ✓ High diversity ecosystem (from clinical data) ✓ Full ecosystem ✓
Slide 7: Looking ahead: addressing growing market opportunities with severe medical need
Looking ahead: addressing growing market opportunities with severe medical need MaaT03X MaaT03X MaaT033 >200,000 patients1 ~ 22,000 patients1 MaaT013 ~ 2,000 patients1 Long-term 3rd line Improvement Solid Tumors in of survival for combination with Expansion SR GI 10x >10x TAM aGvHD allo-HSCT ICI (Im
Slide 8: Hemato-Oncology
\ oe T Hemato-Oncology Jc 2 & 7. ve A ”
Slide 9: MaaT013 and MaaT033 aim to restore the gut microbiota to improve survival
MaaT013 and MaaT033 aim to restore the gut microbiota to improve survival in patients with liquid tumors Intestinal dysbiosis is associated with higher mortality in hemato-oncology Chemotherapy Allogenic Hematopoietic Stem Cell Patients with liquid Antibiotics Transplantation (allo-HSCT) tumors Irra
Slide 10: Hemato-Oncology: Treatment of acute Graft-vs-Host-Disease (aGvHD)
Hemato-Oncology Treatment of acute Graft-vs-Host-Disease (aGvHD)
Slide 11: MaaT013: restore the microbiome to cure gastrointestinal acute GvHD
aGvHD MaaT013: restore the microbiome to cure gastrointestinal acute Graft vs. Host Disease Characteristics Pooled microbiota: a high-richness, high-diversity, full ecosystem, Microbiome Ecosystem Therapy containing ButycoreTM Administration 3 doses (enema bag) Available Clinical Data ✓ HERACLES Pha
Slide 12: HERACLES Phase 2 Clinical Trial results
aGvHD Phase 2 HERACLES Phase 2 Clinical Trial Promising results in a very severe (III-IV) GI aGvHD population • N=24 patients, 96% grade III (4% grade IV), 2nd line (Steroid-resistant) • Very good safety and tolerability profile • MaaT013 increases responders’ gut microbiome diversity Gastro Intesti
Slide 13: Early Access Program is corroborating positive data in advanced GI aGvHD
aGvHD EAP Early Access Program (EAP) is corroborating positive data in an advanced, severe and more diverse GI aGvHD population • N=81 84% SR; Grade III (51%) or Grade IV (38%) aGvHD*, Up to 6 lines of prior treatment (median 2; 66/81 received ruxolitinib) • Good tolerability and safety profile in a
Slide 14: Excellent response to MaaT013 in ruxolitinib-refractory patients
aGvHD EAP Among 81 patients in EAP, excellent response to MaaT013 was shown in n=31 corticoid and ruxolitinib-refractory patients • N=31 - Ruxolitinib-refractory in 2nd line, MaaT013 given in 3rd line • Clinical response to MaaT013 translates to an important increased overall survival • Data present
Slide 15: The ARES Phase 3 study is designed to establish MaaT013 as 3rd line agent
aGvHD The ARES Phase 3 study is designed to establish MaaT013 Phase 3 as the 3rd line agent in GI aGvHD treatment • Further investigation currently ongoing in a pivotal single arm Phase 3 trial of MaaT013 as 3rd line • 75 patients with GI aGvHD who are refractory to both steroids and ruxolitinib • P
Slide 16: Hemato-Oncology: Improving survival in allo-HSCT patients
Hemato-Oncology Improving survival in allogenic Hematopoietic Stem Cell Transplantation patients
Slide 17: MaaT033: An oral capsule as adjunctive and maintenance therapy
Hemato- MaaT033: An oral capsule to be used as an adjunctive and Oncology maintenance therapy for patients with hematological malignancies receiving HSCT Characteristics Pooled microbiota: high-richness, high-diversity, full ecosystem, Microbiome Ecosystem Therapy containing ButycoreTM Administratio
Slide 18: MaaT033's MOA aims to restore and protect the gut microbiota
Allo-HSCT MaaT033’s MOA aims to restore and protect the gut microbiota, to improve overall survival in allo-HSCT patients MaaT033 ✓ High richness and diversity Reset microbial network ✓ ButycoreTM Immune homeostasis Restored barrier Integrity restoration (prevention of infection) ↗ Diversity Inhibit
Slide 19: Phase Ib CIMON study: Positive dose ranging study
AML Phase Ib CIMON study: Positive dose ranging study with promising Phase 1 engraftment and safety data Data presented at ASH 2022 Phase Ib study aimed to determine MaaT033 MaaT033 induces an increased MaaT033 bacterial engraftment is inversely dose for further clinical development microbiota richn
Slide 20: CIMON results open an attractive market opportunity in allo-HSCT
MaaT033 Allo-HSCT CIMON results open an attractive market opportunity: Improving survival in patients receiving allo-HSCT 100% United States EU 5 Japan c. 7,800 c. 9,600 c. 3,000 primary primary primary procedures procedures procedures CIMON Additional 7%-10% recurrent procedures AML : acute myeloid
Slide 21: The Phase 2b is designed to establish MaaT033 as adjunctive and maintenance treatment
MaaT033 The Phase 2b is designed to establish MaaT033 as an adjunctive Allo-HSCT and maintenance treatment for patients with hematological malignancies receiving HSCT • 387 patients in a randomized, double-blind, placebo-controlled international study • Primary endpoint: efficacy of MaaT033 in impro
Slide 22: Immuno-Oncology: Solid Tumors
Immuno-Oncology Solid Tumors
Slide 23: A diverse gut microbiome increases survival in patients receiving ICI
I/O A diverse gut microbiome increases survival in patients receiving immune checkpoint inhibitors (ICI) FMT from ICI responders to ICI non-responding • Immune check-point inhibitors (ICI) therapies have patients with metastatic melanoma established themselves as key therapeutic options in solid tum
Slide 24: MaaT013 ensures high diversity and contains strains that improve ICI response
MaaT013 I/O MaaT013 ensures high diversity and contains specific bacterial Sponsored by strains that have been identified to improve ICI response Higher microbiome richness → better response rate to ICI in patients with metastatic melanoma MaaT013 Gopalakrishnan et al, Science 2018 Ongoing Phase IIa
Slide 25: Proprietary gutPrint platform generates indication-specific microbiome ecosystem therapies
MaaT03X Proprietary gutPrint® platform synergizes multi-source data to I/O generate innovative and indication-specific microbiome ecosystem therapies gutPrint® is the engine that drives MaaT Pharma’s MET product candidate generation capabilities to broaden and strengthen the pipeline ✓ Full cycle in
Slide 26: MaaT03X: Modulate the gut microbiome to improve response to ICI
MaaT03X MaaT03X: Modulate the gut microbiome to improve response I/O to Immune Checkpoint Inhibitors treatment in solid tumors Customizable, donor-independent, Characteristics scalable co-culture process High richness, co-cultured, designed ecosystem Original microbial ecosystem cultures Administrat
Slide 27: Neuro-degenerative diseases: Amyotrophic Lateral Sclerosis (ALS)
Neuro-degenerative diseases: Amyotrophic Lateral Sclerosis (ALS)
Slide 28: Amyotrophic Lateral Sclerosis: an uncurable disease
ALS Amyotrophic Lateral Sclerosis: a uncurable disease leading to death within 3-5 years after diagnosis Neuro-Inflammation RNA metabolism dysfunction Oxydative stress Mitochondria ALS Metabolism alteration dysfunction Glutamate Protein aggregation excitotoxicity ~ 60,000 patients Paralysis No curat
Slide 29: IASO trial: potential first oral microbiotherapy in ALS
ALS IASO trial is designed to develop the potential first oral microbiotherapy in ALS* • Up to 15 patients in a pilot, open-label, Phase 1b study in France Study developed with: • Study is expected to start in H1 2023, results are expected in H1 2024 With the support of Key study endpoints: • Assess
Slide 30: End-to-End in-house cGMP manufacturing
End-to-End in-house cGMP manufacturing
Slide 31: Building Europe's largest specialized cGMP manufacturing facility for MET
Building Europe’s largest specialized cGMP manufacturing facility for Microbiome Ecosystem Therapies Building a dedicated 1,600m2 site (which could be doubled) to support up to 2034 needs of clinical and then commercial Partnership with production of native MET (MaaT013 & MaaT033) and R&D and clinic
Slide 32: Upcoming key milestones
i") fe) Cc (e) ru) i") ov = D> oO ~ on c = (e) 1S) ok
Slide 33: Meaningful milestones in both the near and long term
Meaningful milestones in both the near and long term DSMB Interim safety analysis/ 2022 2023 2024 2025 2026 Internal stopping rules data review Results Launch H1 H2 H1 H2 H1 H2 H1 H2 H1 H2 Graft-vs-Host-Disease ORR OS Phase 3 ARES MaaT013 (pooled enema) in EU (pivotal)1 FDA & EMA Orphan Drug Designa
Slide 34: Key differentiators of MaaT Pharma from other microbiome competitors
Key differentiators of MaaT Pharma from other microbiome competitors Leveraging the complexity of Manufacturing the microbiome versatility Pioneering a full ecosystem approach In-house cGMP manufacturing to restore host/microbiome immune scalability for both native and symbiosis, based on proprietar
Slide 35: A highly experienced team
A highly experienced team BOARD OF DIRECTORS Karim Dabbagh * Chairman of the Board Hervé Affagard Siân Crouzet President – CEO Second Genome Founder & CEO Chief Financial Officer Nadia Kamal * Non-Executive Director Director of the Technology, Health, and Innovation Divisions – Harmonie Mutuelle Jea
Slide 36: Corporate Social Responsibility
Corporate Social Responsibility MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome. Patients are our priority. We are committed t
Slide 37: Thank you
THANK YOU [email protected] +33 4 28 29 14 00 37